Kotak Healthcare Fund Regular-Growth
Mid CapEquity: Sectoral-PharmaVery High Risk
PaisaSmart ratingNot rated yet
Why this rating
This fund is not currently rated by our system. However, we continuously review and update our ratings, so it may be included in the future.
Our score weighs long-term performance, risk and consistency — not just past returns.
Returns
As of 7 Oct 2026
1W
+0.73%
1M
-0.45%
3M
+5.63%
6M
+29.66%
9M
+24.39%
1Y
+26.11%
2Y
+11.76%
Since launch
+20.40%
Portfolio
As of 31 Aug 2026
Market-cap split
Large cap35.00%Mid cap20.97%Small cap44.03%
P/E
50.26
P/B
6.47
Style
Growth
Sector allocation
Healthcare98.17%
Chemicals1.49%
Holdings (36)
| Holding | % of fund | Value | Shares |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 13.96% | ₹107.18 Cr | 5,40,000 |
| Divi's Laboratories Ltd. | 9.25% | ₹71 Cr | 75,000 |
| Torrent Pharmaceuticals Ltd. | 4.75% | ₹36.48 Cr | 72,000 |
| Molbio Diagnostics Ltd. | 4.53% | ₹34.76 Cr | 3,20,000 |
| Max Healthcare Institute Ltd. | 4.34% | ₹33.35 Cr | 3,20,000 |
| Acutaas Chemicals Ltd. | 3.91% | ₹30.03 Cr | 95,000 |
| Cipla Ltd. | 3.67% | ₹28.18 Cr | 2,00,000 |
| Park Medi World Ltd. | 3.36% | ₹25.79 Cr | 9,00,000 |
| Yatharth Hospital & Trauma Care Services Ltd. | 3.25% | ₹24.95 Cr | 2,49,000 |
| Apollo Hospitals Enterprise Ltd. | 3.25% | ₹24.92 Cr | 28,000 |
Fund details
In brief
Long term capital growth. Investment in portfolio of predominantly equity & equity related securities of companies engaged in Pharma, Healthcare & allied sectors.
Investment objective
The scheme is to seek to generate long term capital appreciation through investing in equity and equity related securities of companies benefitting directly or indirectly Pharma, Healthcare, and allied sectors.
Exit load
0.5% for redemption within 30 Days
Fund type
Open-ended
Min lumpsum
₹5,000
Min withdrawal
₹1,000
Lock-in
None
SIP
Available
SWP
Available
STP
Available
Purchase cut-off
15:00